eli lilly retatrutide phase 3 trial THIS is not a small step forward. It's a leap. A new of just dropped from and Company… and the results are genuinely unlike anything we've Lilly's triple agonist delivers up

Ward NC, Wu JH, Clarke MW, Puddey IB, Burke V, Croft KD, Hodgson JM

Exploratory endpoints included here are total and regional BMD, lipid profile, hsCRP, grip strength, fasting insulin and free testosterone levels at weeks 48 and 72 and adipokines, total caloric intake and protein intake at week 48

Endocrine Effects Research has explored DSIPs ability to modulate the release of various hormones such as luteinizing hormone (LH), growth hormone (GH), and corticotropin

In patients that qualify, HGH therapy with peptides such as ipamorelin is a safe yet more cost-effective solution than growth hormone replacement therapy